首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1897327

重组疫苗市场规模、份额及成长分析（按类型、疾病、最终用户、通路及地区划分）－2026-2033年产业预测

Recombinant Vaccines Market Size, Share, and Growth Analysis, By Type, By Disease, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，重组疫苗市场规模将达到 112 亿美元，到 2025 年将达到 124.7 亿美元，到 2033 年将达到 295.8 亿美元，在预测期（2026-2033 年）内，复合年增长率为 11.4%。

重组疫苗代表着疫苗接种策略的模式转移，它摒弃了依赖病原体暴露的传统方法。这些疫苗利用基因工程、基因组学和重组DNA技术的进步，在受控的实验室环境中设计，并采用基因筛检来降低与感染疾病相关的风险。这种创新方法提高了疫苗的有效性和安全性，代表着疫苗研发领域的重大进步。透过实现更精准、更个人化的免疫接种过程，重组疫苗能够有效应对各种健康挑战。这项发展不仅加强了公共卫生应对能力，也凸显了疫苗技术持续进步的巨大潜力，使其成为医疗保健市场值得关注的领域。

重组疫苗市场驱动因素

重组疫苗市场的成长主要得益于重组技术的广泛应用，该技术显着提高了疫苗的安全性和有效性。这项技术能够实现疫苗的快速大规模生产，缓解供不应求，确保供应稳定。此外，重组疫苗不含感染性病毒颗粒，因此对免疫力的人更为安全。这些卓越的疫苗特性促使生产者致力于研发对抗病毒性疾病的新产品。为此，他们正积极利用先进的DNA技术、基因组学和其他前沿生物技术方法，开发更有效、更安全的疫苗。

重组疫苗市场限制因素

重组疫苗市场面临许多挑战，阻碍其成长，其中高成本是一大障碍。儘管世界卫生组织（世卫组织）等机构正积极努力，透过在全球分发数百万剂疫苗来扩大免疫接种范围，但这些疫苗的高昂价格仍然是许多地区面临的一大难题。儘管各方努力改善疫苗的可及性，并覆盖服务不足的社区，但由于价格过高，许多地区仍然难以获得疫苗。此经济因素持续构成重大限制，影响各社区疫苗接种计画的整体有效性。

重组疫苗市场趋势

由于全球感染疾病率不断上升，以及对有效疫苗接种策略的迫切需求，重组疫苗市场正经历显着成长。某些人群，特别是老年人和儿童，日益增长的脆弱性进一步推动了对这些先进疫苗的需求。联合国儿童基金会和泛美卫生组织等机构在促进疫苗快速分发、满足紧急医疗需求以及增强社区对各种病原体的抵抗力方面发挥关键作用。这些国际组织的坚定承诺不仅遏制了疾病传播，也促进了重组疫苗领域的创新和发展，使其成为现代医疗保健策略的重要组成部分。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Pfizer Inc.（United States）
GlaxoSmithKline plc（GSK）（United Kingdom）
Merck & Co., Inc.（United States）
Moderna, Inc.（United States）
Novavax, Inc.（United States）
Johnson & Johnson（United States）
AstraZeneca plc（United Kingdom）
Bavarian Nordic A/S（Denmark）
BioNTech SE（Germany）
Vaxart, Inc.（United States）
Transgene SA（France）
GeoVax Labs, Inc.（United States）
Vaxcyte, Inc.（United States）
Green Cross Corporation（GC Biopharma）（South Korea）
Bharat Biotech International Limited（India）
Shantha Biotechnics Limited（India）
Valneva SE（France）
Inovio Pharmaceuticals, Inc.（United States）
Sinovac Biotech Ltd.（China）

结论与建议

简介目录

Product Code: SQMIG35A2787

Recombinant Vaccines Market size was valued at USD 11.2 Billion in 2024 and is poised to grow from USD 12.47 Billion in 2025 to USD 29.58 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).

Recombinant vaccines represent a paradigm shift in immunization strategies, moving away from conventional methods that relied on pathogen exposure. Leveraging advancements in genetic engineering, genomics, and recombinant DNA technologies, these vaccines are designed in controlled laboratory settings, employing genetic screening to mitigate risks associated with infectious diseases. This innovative approach enhances both the efficacy and safety of vaccines, marking a substantial improvement in vaccine development. By allowing for a more precise and tailored immunization process, recombinant vaccines are positioned to address various health challenges effectively. This evolution not only strengthens public health responses but also highlights the potential for ongoing advancements in vaccine technology, making it an exciting area in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

The growth of the recombinant vaccines market is significantly driven by the widespread adoption of recombinant technology, which greatly improves the safety and effectiveness of vaccines for patients. This technology allows for the rapid and large-scale production of vaccines, reducing supply shortages and ensuring availability. Additionally, recombinant vaccines are free from infectious viral particles, making them safer for those with weakened immune systems. The positive attributes of these vaccines have motivated manufacturers to concentrate on innovating new products aimed at combating viral diseases. This focus involves utilizing advanced DNA technology, genomics, and other state-of-the-art biotechnological approaches to develop vaccines that are not only more effective but also safer overall.

Restraints in the Recombinant Vaccines Market

The Recombinant Vaccines market faces several challenges that hinder its growth, with the high cost per dose being a primary obstacle. Although global health organizations are actively working to enhance vaccination efforts by distributing millions of doses worldwide, the expensive nature of these vaccines remains a significant barrier for various populations. Even as initiatives aim to improve access and reach underserved areas, many regions still experience difficulties in obtaining vaccines due to their prohibitive costs. This economic factor continues to be a major limitation, impacting the overall effectiveness of vaccination programs across different communities.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is experiencing significant growth driven by the rising global incidence of infectious diseases and the urgent need for effective immunization strategies. The heightened vulnerability of specific demographics, particularly the elderly and pediatric populations, amplifies the demand for these advanced vaccines. Organizations like UNICEF and PAHO are pivotal in facilitating the swift distribution of vaccine doses, addressing emergency healthcare needs, and enhancing community resilience against various pathogens. This robust engagement from international bodies not only mitigates disease transmission but also fosters innovation and development within the recombinant vaccine sector, positioning it as a critical component of modern healthcare strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2026-2033)

Market Overview
Subunit recombinant vaccines
Attenuated recombinant vaccines
Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2026-2033)

Market Overview
Pneumococcal Disease
Cancer
Hepatitis B
Influenza
DPT
Others

Global Recombinant Vaccines Market Size by End User & CAGR (2026-2033)

Market Overview
Pediatric
Adult
Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital & Retail Pharmacies
Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2026-2033)

North America (Type, Disease, End User, Distribution Channel)
- US
- Canada
Europe (Type, Disease, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Disease, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Disease, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Disease, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bavarian Nordic A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxart, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeoVax Labs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxcyte, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (GC Biopharma) (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech International Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shantha Biotechnics Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valneva SE (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments